Interview: Mark Yang, Country Manager, Hospira Taiwan
In 2010, you began your last interview with us by mentioning two things: that because of the nature of this affiliate’s portfolio—with only 35% of revenues generated by pharma at…
Address: 18F, 333 DunHua S. Rd., Sec. 2, DaAn District, Taipei 10669, 10669 台北市敦化南路二段333號18樓,Taiwan
Tel: +886 3 3865117
Hospira is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness™ through the right people and the right products. As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions.
The name ‘Hospira’ is derived from the words hospital, spirit, inspire and the Latin word spero, which means hope. It reflects the company’s primary market focus and expresses the hope and optimism that are critical in the healthcare industry.
Hospira focuses mainly on medical devices in the Taiwanese market, but is currently looking to expand its portfolio and increase its offering of generic drugs.
In 2010, you began your last interview with us by mentioning two things: that because of the nature of this affiliate’s portfolio—with only 35% of revenues generated by pharma at…
What is exciting about the Taiwanese market for Hospira today? Hospira is a US-based company, which used to be part of Abbott Laboratories. A major part of the portfolio for…
Dr. Liu, President and CEO of EirGenix, talks about why he sees Taiwan as the ideal market for a CDMO like Eirgenix, why he believes that despite the skepticism, biosimilars…
Whaijen Soo, Managing Director of Supra Integration and Incubation Center (Si2C) speaks about Taiwan’s biotech industry, emphasizing the need for risk tolerance and understanding investing rationale in propelling Taiwan’s industry…
Audrey Tseng, Deputy Chairman of PwC Taiwan with PwC Partners Lily Wong and Andy Chang, delve into factors behind the booming pharma and biotech industry in Taiwan, how to prevent…
Dr Yu-Ray Chen, Professor of Surgery at Chang Gung Memorial Hospital discusses the current state of Taiwan’s healthcare system, highlighting the fact that its current condition is unsustainable in the…
Michael Chiang, the Executive President of Panion & BF Biotech speaks about the incredible growth of the company over the past year, what has contributed to this success and where…
James Wang, Country Managing Partner of Ernst & Young Taiwan explains why Taiwan’s DIG (Diversify-Innovative-Globalize) strategy is crucial for the growth of Taiwan’s economy over the next decade, why biotech…
Full service CRO Choice Pharma moved its operations from Europe to Asia in 2008, and since then the company has thrived. The managing director and business director for the company…
A 2006 article in CommonWealth Magazine detailing the genesis of this company reported that TLC had managed to “break out from the typical dilemma of ordinary biotech firms—to either engage…
The president of Pharmaceutical Industry Technology and Development Center (PITDC) considers the company’s need to remain an international competitor and how to achieve it, the gap in new drug development…
General Manager, Chugai Pharma Taiwan and President of International Research-Based Pharmaceutical Manufacturers’ Association (IRPMA), discusses the continuous price cuts that plague the Taiwan market, and how IRPMA is getting involved…
The CEO of ASLAN Pharmaceuticals discusses the fundamental changes that need to occur in the treatment of serious illnesses, the advantages of building a second branch in Taiwan, and the…
The chairman of Taipei Medical University (TMU) discusses the key challenges TMU has faced over the years, how these challenges will continue to affect the future, and what international accreditation…
See our Cookie Privacy Policy Here